Hyaluronic acid products for osteoarthritis of the knee

Canadian Pharmacists Journal

Volumn 140, Issue 3, 2007, Pages 194-196

  Campbell, Jackie ^a   Ruddock, Brent ^a  

^a Ontario Pharmacists' Association Drug Information and Research Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CORTICOSTEROID DERIVATIVE; DUROLANE; FERMATHRON; HYALURONIC ACID; NEOVISC; NONSTEROID ANTIINFLAMMATORY AGENT; OSTENIL; PLACEBO; SODIUM CHLORIDE; SUPLASYN; UNCLASSIFIED DRUG;

ARTHRALGIA; BREAKTHROUGH PAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FOLLOW UP; FUNCTIONAL ASSESSMENT; HEALTH CARE COST; HEAT; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE INFLAMMATION; JOINT EFFUSION; KNEE OSTEOARTHRITIS; META ANALYSIS; PAIN; PAIN ASSESSMENT; PSEUDOSEPSIS; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SHORT SURVEY; SIDE EFFECT; SWELLING; SYNOVIAL FLUID; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 34249325879     PISSN: 17151635     EISSN: None     Source Type: Journal    
DOI: 10.1177/171516350714000325     Document Type: Short Survey

References (27)

1. Williams J, Badley E. Epidemiology of arthritis and osteoporosis. In: Arthritis and related conditions. Toronto: Institute for Clinical Evaluative Sciences; 1998. Available: www.ices.on.ca/file/Arth-chp1-.pdf (accessed August 27, 2006).
2. Ontario Ministry of Health and Long-Term Care. Intra-articular viscosupplementation with Hylan G-F 20 to treat osteoarthritis of the knee. Health Technology Literature Review. June 2005. Available: www.health.gov.on.ca/ english/providers/program/mas/tech/reviews/pdf/rev_hylan_061705.pdf (accessed August 8, 2006).
3. Jordan KM, Arden NK, Doherty M, et al. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62(12):1145-55.
4. DiPiro JT, Talbert RL, Yee GC, et al, eds. Pharmacotherapy: a pathophysiologic approach. 6th ed. New York: McGraw-Hill; 2005.
5. Lo GH, LaValley M, McAlindon T, Felson DT. Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysis. JAMA 2003;290(23):3115-21.
6. Dagenais S. Intra-articular hyaluronic acid (viscosupplementation) for knee osteoarthritis. Issues Emerg Health Technol 2006;94:1-4.
7. Bellamy N, Campbell J, Robinson V, et al. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2006 Apr 19;(2):CD005321.
8. Wang CT, Lin J, Chang CJ, et al. Therapeutic effects of hyaluronic acid on osteoarthritis of the knee. A meta-analysis of randomized controlled trials. J Bone Joint Surg Am 2004;86-A(3):538-45.
9. Aggarwal A, Sempowski IP. Hyaluronic acid injections for knee osteoarthritis. Systematic review of the literature. Can Fam Physician 2004;50:249-56.
10. Arrich J, Piribauer F, Mad P, et al. Intra-articular hyaluronic acid for the treatment of osteoarthritis of the knee: systematic review and meta-analysis. CMAJ 2005;172(8):1039-43.
11. Gossec L, Dougados M. Do intra-articular therapies work and who will benefit most? Best Pract Res Clin Rheumatol 2006;20(1):131-44.
12. Nesic M, Harrison B, Haziza P. Hylan G-F 20 (Synvisc): reported incidents of joint inflammation and pain. Canadian Adverse Reaction Newsletter 2005;15(2):1. Available: www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/ medeff/carnbcei_v15n2_e.pdf (accessed December 4, 2006).
13. Q-Med AB. Durolane instructions for use. Available: http://pns.q-med. phos-works.net/graphics/1595.pdf (accessed November 24, 2006).
14. Hyalgan. Hyalgan physician information. Available: www.hyalgan.ca/ base_info.html (accessed November 20, 2006)
15. Synvisc product information sheet. November 15, 2004. Available: www.synvisc.com/ussyn__synvisc_pi.pdf (accessed November 24, 2006).
16. Health Canada. Medical Devices Licence Listing [cited November 24, 2006]. Available from: http://mdall.ca/ (accessed March 2, 2007).
17. Duthie L. Medical Devices Bureau, Health Canada. Ottawa, ON. Personal communication; November 28, 2006.
18. Hinberg I. Medical Devices Bureau, Health Canada. Ottawa, ON. Personal communication; November 28, 2006.
19. Q-Med AB. NASHA - the monograph. Uppsala, Sweden; 2001.
20. Biomet Europe. Fermathron. Available: www.biomet.co.uk/index.php?id=7032 (accessed August 23, 2006).
21. Stellar Pharmaceuticals Inc. NeoVisc product information sheet. London, ON; (undated).
22. Rivex Pharma Inc. OrthoVisc comprehensive product monograph. New York: Anaka Therapeutics, Inc.; 2003.
23. Ostenil. Ostenil product monograph. Available: www.ostenil.ca/ostenilR/ monographie-de-produit/ (accessed July 31, 2006)
24. Ferland D. Garvinci International Inc. St-Eustache, QC. Personal communication; August 28, 2006.
25. Supartz. Supartz package insert. Available: www.supartz.com/pdfs/ PackageInsert.pdf (accessed July 31, 2006).
26. LePage J. Smith & Nephew, Inc. St-Laurent, QC. Personal communication; November 24, 2006.
27. Bioniche Pharma (Canada) Ltd. Suplasyn product information sheet. Belleville, ON. February 26, 2004.